COPD is one of the leading cause of chronic morbidity and Mortality in the world. COPD is characterized by by the presence of airflow obstruction and is Partially reversible. However Managing the acute exacerbation of COPD while common is often challenging to most of the Clinicians. Latest Trials shows that administering IV MgSO4 (Magnesium sulfate) in acute cases not responding to inhaled bronchodilators is effective and decrease hospitalisation rate
IV MgSO4 is a Short acting bronchodilator indicated in management of severe asthmatic exacerbation. It acts by inhibiting the influx of calcium into smooth muscle cells of the airway. Its additional actions such as reduced lung hyperinflation and improved respiratory muscle strengths have now helped extend its application to acute COPD exacerbation.
DOSAGE :
2g MgSO4 infused over 20 minutes.
Adverse effects :
IV MgSO4 has excellent safety profile with no major adverse effects.
Contraindications :
1: Renal insufficiency
2: Hypermagnesemia (leads to muscle weakness)
Reference : http://clinicaltrials.gov/ct2/show/NCT03461328
Efficacy of magnesium sulfate in Chronic obstructive Pulmonary disease
https://journals.viamedica.pl >ARM.a2022.0012
